Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community

Bone Marrow Transplant. 2018 Sep;53(9):1170-1179. doi: 10.1038/s41409-018-0123-7. Epub 2018 Mar 16.

Abstract

NK cell activity is tuned by a balance of activating and inhibitory signals transmitted via their respective receptors, including killer immunoglobulin-like receptors (KIRs). The impact of NK cells on graft-versus-leukemia following hematopoietic stem cell transplantation (HSCT) is well established. These effects sometimes lead to GvHD. The link between KIR/HLA interaction and GvHD remains unclear. Herein, we studied the impact of the KIR/HLA interaction on HSCT outcomes in a longitudinal follow-up study of a highly consanguineous HLA-matched related cohort. Peripheral blood DNA was collected from HSCT donor-recipient pairs (n = 87), including 41 AML pairs. KIR and HLA were genotyped and significant results were only measured when matching KIR (donor) with HLA (recipients). GvHD was observed in 47% of patients. KIR2DL1_C2 and 2DS2_C1 (P = 0.02 and 0.04, respectively) matching was associated with an increased incidence of acute GvHD in AML donor-recipient pairs. The rate of chronic GvHD also rose in AML patients who were matched for KIR2DS1_C2 (P = 0.004) and had either KIR2DL2 or KIR2DS2 (P = 0.03). In conclusion, matching of KIR2DL1, 2DS1, and 2DS2 in donors with their HLA-C ligands in recipients is associated with increased GvHD, and holds potential for selection of HSCT donors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cohort Studies
  • Consanguinity*
  • Donor Selection
  • Female
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / immunology
  • HLA-C Antigens / genetics*
  • Hematopoietic Stem Cell Transplantation / methods*
  • Histocompatibility
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / genetics*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prognosis
  • Receptors, KIR / genetics*
  • Receptors, KIR2DL1 / genetics*
  • Young Adult

Substances

  • HLA-C Antigens
  • KIR2DL1 protein, human
  • KIR2DS1 protein, human
  • KIR2DS2 protein, human
  • Receptors, KIR
  • Receptors, KIR2DL1